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Abstract
Background: Renal function is an important predictor of mortality in patients with myocardial infarction (MI), but
changes in the impact over time have not been well described.
We examined the importance of renal function by estimated GFR (eGFR) and se-creatinine as an independent
long-term prognostic factor.
Methods: Prospective follow-up of 6653 consecutive MI patients screened for entry in the Trandolapril Cardiac
Evaluation (TRACE) study. The patients were analysed by Kaplan-Meier survival analysis, landmark analysis and Cox
proportional hazard models. Outcome measure was all-cause mortality.
Results: An eGFR below 60 ml per minute per 1.73 m
2, consistent with chronic renal disease, was present in 42%
of the patients. We divided the patients into 4 groups according to eGFR. Overall, Cox proportional-hazards models
showed that eGFR was a significant prognostic factor in the two groups with the lowest eGFR, hazard ratio 1,72
(confidence interval (CI) 1,56-1,91) in the group with the lowest eGFR. Using the eGFR group with normal renal
function as reference, we observed an incremental rise in hazard ratio. We divided the follow-up period in 2-year
intervals. Landmark analysis showed that eGFR at the time of screening continued to show prognostic effect until
16 years of follow-up. By multivariable Cox regression analysis, the prognostic effect of eGFR persisted for 12 years
and of se-creatinine for 10 years. When comparing the lowest group of eGFR with the group with normal eGFR,
prognostic significance was present in the entire period of follow-up with a hazard ratio between 1,97 (CI 1,65-
2,35) and 1,35 (CI 0,99-1,84) in the 2-year periods.
Conclusions: One estimate of renal function is a strong and independent long-term prognostic factor for 10-12
years following a MI.
Background
The prevalence of cardiovascular disease rises with
declining renal function [1-4]. The significance of
impairment of kidney function for cardiovascular out-
come after myocardial infarction (MI) has been exam-
ined in patients with heart failure [5], impaired left
ventricular function [6] and in patients undergoing cor-
onary artery bypass grafting (CABG) [7].
Several studies have examined cardiovascular out-
comes in patients with end-stage renal disease but data
on the risk in patients with lesser degrees of renal
dysfunction and MI is lacking [8-11]. Moreover, several
studies are limited by a short follow-up period and by
relying on serum creatinine (se-creatinine) level, which
is considered a suboptimal indicator of renal function.
Long-term prognosis after myocardial infarction has
generally improved over the last decades [12] and conse-
q u e n t l yi ti so fi n t e r e s tt os t u d yn o tj u s tm a r k e r so f
short- or intermediate term prognosis but rather predic-
tors of long-term - i.e. more than 10 years - prognosis.
In fact, no information on the influence of estimates of
renal function on such long-term prognosis after myo-
cardial infarction is available.
We undertook a retrospective study of 6676 patients
admitted with myocardial infarction and who were
screened for entry in the Trandolapril Cardiac Evaluation
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estimated GFR and s-creatinine and patients were fol-
lowed for up to 17 years to systematically evaluate the
importance of renal function as an independent prognos-
tic factor evaluated at the time of the index infarction.
Methods
Subject and study design
The Trandolapril Cardiac Evaluation Registry (TRACE)
registry has been described in detail previously [13,14].
In brief, the TRACE registry consist of the 6676 MI
patients screened for entry in the TRACE study, which
was a double-blind, randomised, parallel group, placebo-
controlled study of trandolapril versus placebo in
patients with left ventricular dysfunction after MI. The
study was conducted in 27 centres in Denmark and
included consecutive patients admitted with MI. Partici-
pating centres recorded complications on a daily basis,
and performed an echocardiography 2-6 days after the
infarction. The worst status for each complication was
recorded in the register. The diagnostic criteria of myo-
cardial infarction were chest pain and/or electrocardio-
graphic changes suggestive of ischemia or infarction,
accompanied by elevated cardiac enzymes. Left ventricu-
lar systolic function was evaluated in a core lab as wall
motion index using a 9-segment model and a reverse
scoring system. Wall motion index multiplied by 30
approximates left ventricular ejection fraction, hence a
wall-motion index of 1.2 corresponds to an ejection
fraction of 35%. The technique has previously been
described in detail and validated [15]. Of the screened
patients, 1749 (26.2%) were randomised to trandolapril
or placebo in the TRACE study.
The TRACE study was approved by all regional ethical
committees in Denmark and complies with the Declara-
tion of Helsinki. The study was registered with the
National Board of Health and the Danish Data Protec-
tion Agency. All participating patients provided
informed consent.
Estimation of renal function
Se-creatinine was recorded as the first measurement
performed at admission in all patients, and given the
half-life of se-creatinine the measurement represents
kidney function prior to the MI in the vast majority of
the patients. Direct measurement of GFR is often lim-
ited by practical problems, especially in acutely ill
patients. Of several reliable equations, we estimated
GFR (eGFR) with the use of the four-component
MDRD equation incorporating age, race, sex and serum
creatinine level [16]:
EstimatedGFR = 186 × (serumcreatininelevel[inmilligramsperdecilitre])−1,154
× (age[inyears])−0,203
For women the product of this equation was multi-
plied by a correction factor of 0.742. We did not use a
correction factor for race because all included patients
were Caucasian.
We divided eGFR into four categories (less than 45.0
(eGFRgroup 4), greater than or equal to 45.0 and less
than 60.0 (eGFRgroup 3), greater than or equal to 60.0
and less than 75.0 (eGFRgroup 2) and greater than or
equal to 75.0 (eGFRgroup 1) ml per minute per 1.73
m
2), incorporating the guidelines of the National Kidney
Foundation [17].
I no r d e rt oc o m p a r et h ep r o g n o s t i cs i g n i f i c a n c eo f
creatinine and eGFR, we divided se-creatinine into 4
categories (se-creatinine less or equal to 60 (cregroup
1), greater than 60 and less than 75 (cregroup 2), greater
than 120 and less than 180 (cregroup 3), greater than
180 (cregroup 4) μmol/l).
Follow-up data
All Danish citizens are given a unique and permanent
personal identification number that allows cross-linkage
between registries. All deaths in Denmark are registered
in the central person registry within 2 weeks and all
deaths are confirmed by a death certificate. Follow-up
mortality data were provided by a computerized analysis
from the Danish Central Personal Registry by
16.06.2008.
Statistical analysis
eGFR is presented in categories for descriptive purposes
but was used as a continuous variable in statistical tests.
The baseline characteristics of the study population
were compared with a t-test for continuous variables
and a chi-square test for discrete variables. Mortality
was analysed with Kaplan-Meier curves. We used Land-
mark analyses to illustrate the prognostic significance of
renal function in 2-year intervals. All-cause mortality
was compared with multivariable Cox proportional-
hazards regression models. We used stepwise models
including increasing number of variables. Model 1 is a
univariate analysis, model 2 included age and gender
and model 3 in addition included all covariates (Body
mass index, previous AMI, angina pectoris, congestive
heart failure, diabetes mellitus, wall motion index, sys-
temic hypertension, thrombolytic therapy). In all models
either se-creatinine group or eGFR were included in the
model. The model assumptions (linearity of continuous
variables, proportional hazards assumption and lack of
interaction) were fulfilled. All p-values were two-sided,
and a P value of less than 0.05 was considered statistical
significant.
Statistical analyses were performed with the Statistical
Analysis System software package, version 9.1 (SAS
Institute, Cary, NC, USA).
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A total of 7001 MI’s in 6676 patients were reported from
May 1990 to August 1992. By the end of follow-up, death
was reported in 5231 patients (78.4%). A total of 38 non-
Danish patients (0.56%) were censored at the day of hospi-
tal discharge. There were missing data on renal function
in 23 patients, who were excluded from our analyses.
Baseline characteristics of the 6653 patients included
in our study are presented in table 1. Forty-two% had
an estimated GFR below the suggested value for chronic
kidney disease (<60 ml per minute per 1.73 m
2). With
declining renal function patients were older, had more
co-morbidity, were less often treated with thrombolytic
therapy but more often with diuretics, had worse left
ventricular systolic function and were in a more severe
clinical state evaluated by New York Heart Association
(NYHA) and Killip class. There were few patients with
recurrent MI (N = 198, 3,72%) or pulmonary embolism
(N = 27, 0,27%). Only 178 patients (3,33%) were receiv-
ing antiarrhytmic therapy at discharge.
Renal function was inversely related to all-cause mor-
tality (figure 1, unadjusted analysis). The mortality was
43,0% (eGFR group 1), 56,9% (eGFR group 2), 71,9%
(eGFR group 3), 89,7% (eGFR group 4) at 10 years of
follow-up and 57,7% (eGFR group 1), 71,3% (eGFR
group 2), 83,6% (eGFR group 3), 95,4% (eGFR group 4)
at 15 years of follow-up (p < 0.0001 for difference
between the 4 eGFR groups). To clarify the importance
of renal function as prognostic factor we performed a
Landmark analysis illustrating survival stratified by
eGFR group and adjusted for age and sex in 2 year
intervals after the infarction (figure 2). Estimation of
renal function has prognostic significance for up to 16
years following MI, even without adjustment for chan-
ging values of se-creatinine. Landmark analyses of 2-
year periods shows that the statistic significance disap-
pears after 12 years of follow-up, but hazard ratio is
almost the same in the following years, so the lack of
significance in this period is probably a result of lack of
p o w e r .T h eh a z a r dr a t i oi sc l o s et o1 . 0 0o n l ya f t e r1 6
years of follow-up.
We constructed 3 Cox proportional-hazards models of
total mortality with a stepwise addition of covariates
(table 2). In the multivariable analyses we included
demographic factors, comorbidities and information
regarding thrombolytic therapy. We did not include
information regarding complications because of the risk
of immortal time bias. Since clinicians have varying
thresholds for initiating medical therapy, we did not
include information regarding the medical treatment at
discharge in the multivariable analyses because this
could make the interpretation of results very complex
and difficult. Age was a significant prognostic factor
throughout the follow-up in all models. When using
eGFRgroup 1 (normal renal function) as reference in the
model incorporating all covariates in the whole follow-
up period, estimated GFR was a significant prognostic
factor in eGFRgroups 3 (hazard ratio 1,19, CI 1,09-1,30)
and 4 (hazard ratio 1,72, CI 1,56-1,91) but not in
eGFRgroup 2 (hazard ratio 0,99, CI 0,91-1,07)(figure 3).
Overall, there was a rise in hazard ratio with worsening
renal function. eGFR was a prognostic factor for 12
years and s-creatinine for 10 years, with the exception
of the follow-up period from 6-8 years where signifi-
cance was only borderline. Restricting the analysis to
eGFRgroup 4 (lowest eGFR group) and eGFR group 1
(normal eGFR), prognostic significance was observed in
the entire period of follow-up with hazard ratio between
1,97 (CI 1,65-2,35) and 1,35 (CI 0,99-1,84). In all 2-year
periods statistical significant impact of eGFR was found,
with the exception of the last follow-up period, which
was probably a result of a lack of statistical power. Also,
the analysis of the 4-6 year period of follow-up showed
borderline significance, again likely due to a lack of
power. When we controlled the Cox-model incorporat-
ing all covariates for whether the patients received ACE-
inhibitor, eGFR statistical significance was lost in the 4-
6 years follow-up period, while the other results were
not significantly changed (data not shown).
In order to examine whether the prognostic signifi-
cance of renal function was different in patients revascu-
larized with thrombolysis, we performed an interaction
analysis between renal function and trombolysis. We
found a significant interaction between creatinine
groups and thrombolysis with a p-value of 0.007. The
overall hazard ratio was 1.374 (CI 1.289-1.464) with a
hazard ratio in the group not treated with thrombolysis
of 1.367 (CI 1.281-1.460) and 1.149 (CI 1.030-1.281) in
the group treated with trombolysis. Similarly, an interac-
tion was seen between eGFRgroup and thrombolysis
with a p-value of 0.001. The overall hazard ratio was
1.242 (CI 1.194-1.292), with a hazard ratio of 1.235 (CI
1.186-1.287) in the group not treated with thrombolysis
and 1.128 (CI 1.068-1.191) in the group treated with
thrombolysis. In conclusion, the prognostic significance
was greatest in the group not treated with thrombolysis,
but as can be seen from the numbers, the interaction
was not due to a large difference in hazard ratio asso-
ciated with a decrease in renal function.
Discussion
We found that renal function measured during the
index hospitalization was an independent significant
prognostic factor more than 10 years after MI.
Ideally, the evaluation of renal function should be per-
formed by direct GFR measurement, but this approach
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eGFR group 1
eGFR ≥ 75.0 ml per
minute per 1.73 m
2
(n = 1772)
eGFR group
2 60.0 ≤≤ 74.9 ml per
minute per 1.73 m
2
(n = 2071)
eGFR group 3
45 ≤≤ 59.9 ml per
minute per 1.73 m
2
(n = 1726)
eGFR group 4
eGFR <45 ml per
minute per 1.73 m
2
(n = 1107)
P
Value*
Age (SD) 59.7 66.6 71.1 75.0 <0.0001
Gender,%
Women 16.9 28.4 42.5 49.9 <0.0001
Men 83.1 71.6 57.5 50.1
Body mass index
(SD)
25,8 25.9 25.6 25.2 <0.0001
Creatinine (mean),
μmol/l
80.1 95.6 112.1 174.5 <0.0001
Hypertension,% 15.9 20.4 25.8 32.8 <0.0001
Diabetes,% 6.7 9.8 12.1 17.2 <0.0001
Angina pectoris% 27.5 36.0 42.1 45.2 <0.0001
Previous MI,% 17.0 22.6 26.0 30.8 <0.0001
Heart failure,% 34.2 48.8 64.1 77.3 <0.0001
Smoking,%
Previously 16.9 22.2 24.9 25.1 <0.0001
Currently 65.8 52.9 44.5 36.2
Thrombolysis,% 49.7 45.3 37.4 23.7 <0.0001
Previous stroke,% 4.6 7.0 9.4 14.2 <0.0001
Diuretic treatment,%
***
25.2 40.2 53.7 70.0 <0.0001
Digoxin at
discharge,%***
7.2 13.9 21.0 31.3 <0.0001
ACE inhibitor at
discharge,%***
4.2 5.8 9.8 15.3 <0.0001
NYHA,%
Class I 68.3 62.2 51.6 38.9 <0.0001
Class II 25.6 27.6 31.4 33.4
Class III 2.2 3.8 5.4 6.6
Class IV 2.6 4.3 7.8 15.5
Killip**,%
Class I 88.6 82.8 74.2 62.8 <0.0001
Class II 9.1 13.5 18.6 21.9
Class III 0.5 1.3 2.6 5.4
Class IV 1.9 2.3 4.7 9.9
Wall motion index,
%
>1,6 42.5 33.4 28.9 21.8 <0.0001
1,3-1,6 24.7 24.5 22.4 21.8
0,8-1,2 26.2 33.1 35.4 34.2
<0,8 2.0 4.0 6.3 9.8
Not classified 4.5 5.0 7.0 12.6
Ventricular
fibrillation.%****
5.4 6.5 9.3 8.0 <0.0001
Ventricular
tachycardia,%****
12.2 12.8 13.1 12.6 0.8744
Atrial fibrillation,%
****
12.3 18.2 25.6 32.4 <0.0001
*for difference between groups.
** Worst Killip class during index hospitalization
SD, standard deviation; NYHA, New York Heart Association;
P-values calculated with the use of chi
2-test for discrete variables and t-test for continuous variables.
***At discharge.
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dies have used se-creatinine instead of GFR to evaluate
renal function. However, the association between se-
creatinine and GFR is nonlinear, because it varies with
age, gender, ethnicity and lean body mass, which limits
the value of serum creatinine level as a marker of renal
function [18-20]. As a result, the National Kidney Foun-
dation uses GFR, not serum creatinine, to define chronic
kidney disease [17,19]. Of the several reliable formulas
incorporating clinical variables, we used the MDRD for-
mula, which has previously been used in 2 large studies
[11,18]. However, a study by Szummers showed that
Cockcroft-Gault formula was better than the MDRD
equation at predicting mortality after a MI. This was
mainly explained by differences in the coefficients and
variables included in the eGFR equations, and less to
differences in various subgroups of patients [21]. The
limited value of se-creatinine measurement was illu-
strated in our study by modest differences in se-creati-
nine between eGFR groups 1-3, despite large differences
in eGFR which were also associated with differences in
all-cause mortality. Nevertheless, despite its shorter per-
sistence, se-creatinine level was as strong a prognostic
factor as eGFR. The hazard ratios for creatinine groups
were slightly higher than for eGFR groups in some 2-
year periods of follow-up, but also more imprecise.
The observed increase in risk of all-cause mortality
with decreasing eGFR is likely explained by factors asso-
ciated with renal decline, for example albuminuria, pro-
teinuria, homocysteinemia [1,2,22]. Elevated uric acid
levels and traditional risk factors for coronary heart dis-
ease are prevalent in patients with chronic kidney dis-
ease [2]. Hypertension may cause or worsen renal
disease and is a significant cause of the accelerated
development of cardiovascular disease [23]. Indeed,
patients with impaired renal function have more severe
and diffuse coronary heart disease [24]. A vicious circle
often exists because the frequency of coronary risk fac-
tors increases with decreasing renal function. In our
study, impaired renal function was associated with a
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Figure 1 Unadjusted all-cause mortality stratified by eGFR group.
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Page 5 of 10higher frequency of hypertension, diabetes, angina pec-
toris and previous MI. Impaired renal function was also
associated with higher age and was more common
among women, both factors which reduce GFR esti-
mated by the MDRD formula. We found that age was a
significant risk factor for all-cause mortality throughout
the length of follow-up, which is in agreement with pre-
vious studies [1,22].
Many patients with decreased renal function are trea-
ted less aggressively with therapeutic interventions and
risk factor modification, a finding documented to paral-
lel a worsening in renal function [25,26]. Patients with
end-stage renal disease, whom are known to be at very
high risk for cardiovascular events, are also treated less
aggressively with prognosis-improving cardiovascular
medications [27,28]. The reason often is a fear of wor-
sening renal function and of drug-induced toxic effects
as a result of low clearance. In our study, fewer patients
received thrombolytic therapy when renal function
decreased. This could be a result of less aggressive
treatment of patients with renal dysfunction, but it is
probably also explained by the age-difference between
patients with decreased and normal renal function, since
the se-creatinine value is usually not known at the time
of initiation of thrombolytic therapy.
The management of patients with decreased renal func-
tion is difficult. On one hand, patients with renal impair-
ment can safely obtain the same benefits of cardiovascular
medications and invasive procedures when appropriately
monitored [29-34]. On the other hand, many of the large
landmark cardiovascular trials have excluded patients with
renal function under a certain limit.
It has been documented that in patients with diabetes,
the prevalence of renal dysfunction is higher, but the
effect of renal function on cardiovascular risk is largely
independent of diabetes status. Thus, a similar risk rela-
tion between renal function and CV risk exists in
patients with and without DM [35].
Several recent papers have examined the prognostic
r o l eo fr e n a lf u n c t i o ni nA M Ip a t i e n t s .O n es t u d y
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Figure 2 Landmark analysis of the time dependent prognostic significance of renal function adjusted for age and gender.
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sening of renal function among patients hospitalised for
MI surviving to hospital discharge. With a follow-up of
at least 4 years, worsening renal function was indepen-
dently associated with diabetes, left ventricular systolic
dysfunction and a history of chronic kidney disease.
After adjustment for factors associated with worsening
renal function and long-term mortality, worsening renal
function was independently associated with a higher risk
of death [36]. In another study, the prognostic signifi-
cance of chronic kidney disease and acute kidney injury
on acute coronary syndrome was reviewed. This study
stressed the importance of early measurement and mon-
itoring of renal function, which is probably standard of
care in most institutions [37]. The significance of creati-
nine clearance at the time of hospital admission as a
predictor of in-hospital adverse events and mortality
was examined using data from the global registry of
acute coronary events (GRACE) comprising 11 774
patients hospitalised with ACS. The results showed that
in comparison with patients with normal or minimally
impaired renal function, patients with moderate renal
dysfunction were twice as likely to die and those with
severe renal dysfunction almost four times more likely
to die after adjustment for other potentially confounding
variables. The risk of major bleeding episodes increased
as renal function worsened [38]. Data from GRACE also
showed that initial serum creatinine concentration was
among the nine factors that independently predicted
death and the combined end point of death and myocar-
dial infarction in the period from admission to six
months after discharge [39]. An observational study of
57477 consecutive MI patients showed that declining
GFR estimated by the MDRD formula was associated
with an increased rate of complications and a higher
rate of in-hospital mortality [40].
The population described here was recruited from 27
Danish hospitals with regional patient uptake and can
be considered representative in a western industrialized
country of patients admitted alive with MI. With declin-
ing renal function, patients in our study were more
often women, were older and had a greater frequency of
comorbidities. This is in accordance with previous stu-
dies [38,40]. We have shown that reduced renal function
is a long-term independent predictor of all-cause mor-
tality in a graded manner. Previous studies have docu-
mented adverse outcomes at 30 and 180 days in patients
with reduced renal function of MI [3,24,41-43]. The
Table 2 Three proportional hazards models of mortality as a function of time with stepwise addition of variables
0-2
years
2-4
years
4-6
years
6-8
years
8-10
years
10-12
years
12-14
years
14-16
years
16-
years
N=
6676
N=
4702
N=
4022
N=
3474
N=
2978
N=
2526
N=
2152
N=
1854
N=
1576
Variables RR CI* RR CI* RR CI* RR CI* RR CI* RR CI* RR CI* RR CI* RR CI*
Model 1
eGFRgroup** 1.77 1.69-
1.85
1.57 1.46-
1.70
1.45 1.33-
1.58
1.43 1.30-
1.56
1.53 1.39-
1.68
1.42 1.27-
1.58
1.40 1.24-
1.58
1.36 1.20-
1.55
1.28 1.04-
1.57
Cregroup 2.09 1.96-
2.23
1.95 1.71-
2.22
1.89 1.61-
2.21
1.58 1.30-
1.91
1.68 1.36-
2.06
1.51 1.17-
1.95
1.55 1.14-
2.10
0.91 0.63-
1.33
1.57 0.93-
2.63
Model 2***
Male gender 1.11 1.00-
1.24
1.45 1.22-
1.73
1.12 0.92-
1.36
1.36 1.10-
1.67
1.22 0.98-
1.51
1.83 1.41-
2.37
1.15 0.88-
1.50
1.22 0.92-
1.61
1.01 0.66-
1.55
Age**** 1.37 1.29-
1.45
1.64 1.50-
1.81
1.66 1.50-
1.84
1.86 1.66-
2.06
1.86 1.66-
2.08
1.91 1.69-
2.18
1.95 1.69-
2.24
1.90 1.63-
2.20
2.10 1.66-
2.67
eGFRgroup** 1.27 1.20-
1.34
1.21 1.11-
1.32
1.12 1.01-
1.23
1.10 0.99-
1.22
1.20 1.07-
1.34
1.19 1.05-
1.35
1.11 0.96-
1.29
1.13 0.97-
1.31
1.01 0.79-
1.29
Cregroup 1.34 1.24-
1.46
1.30 1.12-
1.51
1.47 1.24-
1.74
1.10 0.90-
1.36
1.30 1.05-
1.63
1.25 0.96-
1.62
1.28 0.93-
1.76
0.76 0.52-
1.11
1.35 0.79-
2.32
eGFRgroup
2 vs. 1
1.15 0.98-
1.36
0.86 0.68-
1.08
0.88 0.69-
1.12
1.10 0.86-
1.41
0.92 0.71-
1.20
1.06 0.81-
1.38
0.87 0.64-
1.17
1.08 0.80-
1.45
0.89 0.57-
1.38
eGFRgroup
3 vs. 1
1.48 1.26-
1.75
1.04 0.82-
1.33
1.10 0.85-
1.41
0.89 0.67-
1.18
1.29 0.98-
1.69
1.30 0.96-
1.76
1.10 0.78-
1.53
1.09 0.76-
1.56
0.81 0.46-
1.42
eGFRgroup
4 vs. 1
1.97 1.65-
2.35
1.72 1.32-
2.24
1.35 0.99-
1.84
1.71 1.23-
2.37
1.68 1.16-
2.42
1.84 1.20-
2.83
1.58 0.96-
2.59
1.92 1.13-
3.26
1.89 0.78-
4.55
In all models either cregroup or eGFR were included in the model.
*95% confidence interval
**Hazard ratio associated with 1 eGFR group improvement
***Other covariates in model 2: Body mass index, previous AMI, angina pectoris, congestive heart failure, diabetes mellitus, wall motion index, systemic
hypertension, thrombolytic therapy.
****Hazard ratio associated with an increase in age of 10 years.
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tic effect of renal function in 2-year intervals with a very
long follow-up period. This makes it possible to docu-
m e n tt h el o s so fp r o g n o s t i cs i g n i f i c a n c eo far i s kf a c t o r
in the very long-term.
The relationship between renal function and cardio-
vascular outcomes has previously been examined in sev-
eral large studies: the Studies of Left Ventricular
Dysfunction (SOLVD) trial, Trandolapril Cardiac Eva-
luation (TRACE) trial, Survival and Ventricular Enlarge-
ment (SAVE) trial and 2 analyses of the Valsartan in
Acute Myocardial Infarction Trial (VALIANT)
[4,11,35,44,45]. The SOLVD and SAVE studies and the
analyses from VALIANT used the MDRD formula to
estimate renal function. All these studies found that
reduced renal function was independently associated
with an increased risk of death and cardiovascular out-
comes. Our study also comprises a large cohort but
with a broader spectrum of renal dysfunction, because
all patients in the TRACE register was included irre-
spective of se-creatinine level [11,35]. Together with the
inclusion of consecutive patients we believe this makes
the population studied here is more representative of
daily clinical practice. Moreover, our cohort was fol-
lowed for up to 17 years, far longer than any other
study on this subject. In comparison, the analysis from
VALIANT examined only high-risk patients with clinical
or radiological signs of heart failure and/or left ventricu-
lar systolic dysfunction and the follow-up period was
limited to a median of 24.7 months.
Limitations
Our study has several limitations that should be
acknowledged. The data do not allow us to evaluate the
effect of duration or changes in renal dysfunction. Con-
trast-medium-induced nephropathy related to coronary
angiography cannot be evaluated. The MDRD equation
has limitations, because serum creatinine is influenced
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Page 8 of 10by non-renal factors. The baseline-estimated GFR can be
affected by urinary excretion of protein, which we did
not measure. Our study focuses solely on mortality, with
no information on the effect of renal dysfunction on
nonfatal outcomes. We do not have information regard-
ing how many patients underwent coronary angiography
or CABG during hospital stay or later. This treatment
was not routine at the time of the trial (1992-1994). As
a result, we cannot evaluate whether the frequency of
invasive treatment differ in the eGFRgroups. It has pre-
viously been shown that early invasive therapy defined
as revascularization within 14 days of admission was
associated with greater 1-year survival in patients with
non-ST-elevation myocardial infarction and mild-to-
moderate renal insufficiency, but the benefit declined
with lower renal function [46]. It might be argued that
the long-term prognostic information is of lesser interest
for renal function, which is frequently updated be creati-
nine measurement, than for other risk factors, for exam-
ple systolic function by echocardiography, which is
updated more rarely.
Conclusions
Renal function is a strong and independent long-term
prognostic factor the first 10-12 years following a MI.
Estimating GFR provides a more precise estimate of
renal function than se-creatinine and carries stronger
prognostic significance. We expect that the prevalence
of renal dysfunction among patients with MI will
increase as a result of an ageing population with an
accumulation of risk factors, including hypertension and
diabetes. Consequently, the relevance of the findings of
the present study will be relevant also in the future.
Acknowledgements
Rikke Sørensen, M.D., for help with SAS programming.
Author details
1Dept. of Cardiology, Rigshospitalet, Copenhagen University Hospital,
Denmark.
2Dept. of Cardiology, Gentofte University Hospital, Copenhagen,
Denmark.
3Dept. of Cardiology, Hilleroed University Hospital, Hilleroed,
Denmark.
Authors’ contributions
TK was responsible for all stages of the study with the exception of data
collection and follow-up: Analysis of data, analysis of the literature, and
preparation of the manuscript. GG supervised the entire study, participated
in follow-up, analysis and interpretation of data, and revised the manuscript.
LK supervised the entire study, participated in follow-up, analysis and
interpretation of data, and revised the manuscript. FG aided in analysis and
interpretation of data and revision of the manuscript. MS aided in analysis
and interpretation of data and revision of the manuscript. CT-P conceived
the idea for the study, supervised the study, collected data, analyzed data
and revised the manuscript. All authors have seen and approved the
manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 14 January 2011 Accepted: 27 June 2011
Published: 27 June 2011
References
1. Foley RN, Parfrey PS, Sarnak MJ: Epidemiology of cardiovascular disease in
chronic renal disease. J Am Soc Nephrol 1998, 9(12 Suppl):S16-23.
2. Luft FC: Renal disease as a risk factor for cardiovascular disease. Basic Res
Cardiol 2000, 95(Suppl 1):I72-76.
3. Sarnak MJ, Levey AS: Cardiovascular disease and chronic renal disease: a
new paradigm. Am J Kidney Dis 2000, 35(4 Suppl 1):S117-131.
4. Sorensen CR, Brendorp B, Rask-Madsen C, Kober L, Kjoller E, Torp-
Pedersen C: The prognostic importance of creatinine clearance after
acute myocardial infarction. European heart journal 2002, 23(12):948-952.
5. Hillege HL, Nitsch D, Pfeffer MA, Swedberg K, McMurray JJ, Yusuf S,
Granger CB, Michelson EL, Ostergren J, Cornel JH, et al: Renal function as a
predictor of outcome in a broad spectrum of patients with heart failure.
Circulation 2006, 113(5):671-678.
6. Dries DL, Exner DV, Domanski MJ, Greenberg B, Stevenson LW: The
prognostic implications of renal insufficiency in asymptomatic and
symptomatic patients with left ventricular systolic dysfunction. J Am Coll
Cardiol 2000, 35(3):681-689.
7. Szczech LA, Best PJ, Crowley E, Brooks MM, Berger PB, Bittner V, Gersh BJ,
Jones R, Califf RM, Ting HH, et al: Outcomes of patients with chronic renal
insufficiency in the bypass angioplasty revascularization investigation.
Circulation 2002, 105(19):2253-2258.
8. Chertow GM, Normand SL, Silva LR, McNeil BJ: Survival after acute
myocardial infarction in patients with end-stage renal disease: results
from the cooperative cardiovascular project. Am J Kidney Dis 2000,
35(6):1044-1051.
9. Herzog CA, Ma JZ, Collins AJ: Poor long-term survival after acute
myocardial infarction among patients on long-term dialysis. N Engl J Med
1998, 339(12):799-805.
10. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL,
McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, et al: Kidney disease as a
risk factor for development of cardiovascular disease: a statement from
the American Heart Association Councils on Kidney in Cardiovascular
Disease, High Blood Pressure Research, Clinical Cardiology, and
Epidemiology and Prevention. Hypertension 2003, 42(5):1050-1065.
11. Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL,
White HD, Nordlander R, Maggioni A, Dickstein K, et al: Relation between
renal dysfunction and cardiovascular outcomes after myocardial
infarction. N Engl J Med 2004, 351(13):1285-1295.
12. Setoguchi S, Glynn RJ, Avorn J, Mittleman MA, Levin R, Winkelmayer WC:
Improvements in long-term mortality after myocardial infarction and
increased use of cardiovascular drugs after discharge: a 10-year trend
analysis. J Am Coll Cardiol 2008, 51(13):1247-1254.
13. Kober L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K,
Videbaek J, Cole DS, Auclert L, Pauly NC: A clinical trial of the angiotensin-
converting-enzyme inhibitor trandolapril in patients with left ventricular
dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation
(TRACE) Study Group. N Engl J Med 1995, 333(25):1670-1676.
14. The TRAndolapril Cardiac Evaluation (TRACE) study: rationale, design,
and baseline characteristics of the screened population. The Trace Study
Group. Am J Cardiol 1994, 73(10):44C-50C.
15. Kober L, Torp-Pedersen C, Carlsen J, Videbaek R, Egeblad H: An
echocardiographic method for selecting high risk patients shortly after
acute myocardial infarction, for inclusion in multi-centre studies (as used
in the TRACE study). TRAndolapril Cardiac Evaluation. European heart
journal 1994, 15(12):1616-1620.
16. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate
method to estimate glomerular filtration rate from serum creatinine: a
new prediction equation. Modification of Diet in Renal Disease Study
Group. Ann Intern Med 1999, 130(6):461-470.
17. K/DOQI clinical practice guidelines for chronic kidney disease:
evaluation, classification, and stratification. Am J Kidney Dis 2002, 39(2
Suppl 1):S1-266.
18. Al Suwaidi J, Reddan DN, Williams K, Pieper KS, Harrington RA, Califf RM,
Granger CB, Ohman EM, Holmes DR Jr: Prognostic implications of
abnormalities in renal function in patients with acute coronary
syndromes. Circulation 2002, 106(8):974-980.
Kümler et al. BMC Cardiovascular Disorders 2011, 11:37
http://www.biomedcentral.com/1471-2261/11/37
Page 9 of 1019. Shlipak MG: Pharmacotherapy for heart failure in patients with renal
insufficiency. Ann Intern Med 2003, 138(11):917-924.
20. Walsh CR, O’Donnell CJ, Camargo CA Jr, Giugliano RP, Lloyd-Jones DM:
Elevated serum creatinine is associated with 1-year mortality after acute
myocardial infarction. Am Heart J 2002, 144(6):1003-1011.
21. Szummer K, Lundman P, Jacobson SH, Lindback J, Stenestrand U,
Wallentin L, Jernberg T: Cockcroft-Gault is better than the Modification of
Diet in Renal Disease study formula at predicting outcome after a
myocardial infarction: data from the Swedish Web-system for
Enhancement and Development of Evidence-based care in Heart
disease Evaluated According to Recommended Therapies
(SWEDEHEART). Am Heart J 159(6):979-986.
22. McCullough PA: Cardiorenal risk: an important clinical intersection. Rev
Cardiovasc Med 2002, 3(2):71-76.
23. Benetos A, Waeber B, Izzo J, Mitchell G, Resnick L, Asmar R, Safar M:
Influence of age, risk factors, and cardiovascular and renal disease on
arterial stiffness: clinical applications. Am J Hypertens 2002,
15(12):1101-1108.
24. McCullough PA: Beyond serum creatinine: defining the patient with renal
insufficiency and why? Rev Cardiovasc Med 2003, 4(Suppl 1):S2-6.
25. Al-Ahmad A, Rand WM, Manjunath G, Konstam MA, Salem DN, Levey AS,
Sarnak MJ: Reduced kidney function and anemia as risk factors for
mortality in patients with left ventricular dysfunction. J Am Coll Cardiol
2001, 38(4):955-962.
26. Manjunath G, Tighiouart H, Ibrahim H, MacLeod B, Salem DN, Griffith JL,
Coresh J, Levey AS, Sarnak MJ: Level of kidney function as a risk factor for
atherosclerotic cardiovascular outcomes in the community. J Am Coll
Cardiol 2003, 41(1):47-55.
27. Beattie JN, Soman SS, Sandberg KR, Yee J, Borzak S, Garg M,
McCullough PA: Determinants of mortality after myocardial infarction in
patients with advanced renal dysfunction. Am J Kidney Dis 2001,
37(6):1191-1200.
28. Shlipak MG, Heidenreich PA, Noguchi H, Chertow GM, Browner WS,
McClellan MB: Association of renal insufficiency with treatment and
outcomes after myocardial infarction in elderly patients. Ann Intern Med
2002, 137(7):555-562.
29. Cheung AK, Sarnak MJ, Yan G, Dwyer JT, Heyka RJ, Rocco MV, Teehan BP,
Levey AS: Atherosclerotic cardiovascular disease risks in chronic
hemodialysis patients. Kidney Int 2000, 58(1):353-362.
30. Gottlieb SS, McCarter RJ, Vogel RA: Effect of beta-blockade on mortality
among high-risk and low-risk patients after myocardial infarction. N Engl
J Med 1998, 339(8):489-497.
31. Henry RM, Kostense PJ, Bos G, Dekker JM, Nijpels G, Heine RJ, Bouter LM,
Stehouwer CD: Mild renal insufficiency is associated with increased
cardiovascular mortality: The Hoorn Study. Kidney Int 2002,
62(4):1402-1407.
32. Holdaas H, Fellstrom B, Jardine AG, Holme I, Nyberg G, Fauchald P,
Gronhagen-Riska C, Madsen S, Neumayer HH, Cole E, et al: Effect of
fluvastatin on cardiac outcomes in renal transplant recipients: a
multicentre, randomised, placebo-controlled trial. Lancet 2003,
361(9374):2024-2031.
33. McCullough PA, Wolyn R, Rocher LL, Levin RN, O’Neill WW: Acute renal
failure after coronary intervention: incidence, risk factors, and
relationship to mortality. Am J Med 1997, 103(5):368-375.
34. Tonelli M, Moye L, Sacks FM, Cole T, Curhan GC: Effect of pravastatin on
loss of renal function in people with moderate chronic renal
insufficiency and cardiovascular disease. J Am Soc Nephrol 2003,
14(6):1605-1613.
35. Anavekar NS, Solomon SD, McMurray JJ, Maggioni A, Rouleau JL, Califf R,
White H, Kober L, Velazquez E, Pfeffer MA: Comparison of renal function
and cardiovascular risk following acute myocardial infarction in patients
with and without diabetes mellitus. Am J Cardiol 2008, 101(7):925-929.
36. Amin AP, Spertus JA, Reid KJ, Lan X, Buchanan DM, Decker C, Masoudi FA:
The prognostic importance of worsening renal function during an acute
myocardial infarction on long-term mortality. Am Heart J
160(6):1065-1071.
37. Rodrigues FB, Bruetto RG, Torres US, Otaviano AP, Zanetta DM,
Burdmann EA: Effect of kidney disease on acute coronary syndrome. Clin
J Am Soc Nephrol 5(8):1530-1536.
38. Santopinto JJ, Fox KA, Goldberg RJ, Budaj A, Pinero G, Avezum A, Gulba D,
Esteban J, Gore JM, Johnson J, et al: Creatinine clearance and adverse
hospital outcomes in patients with acute coronary syndromes: findings
from the global registry of acute coronary events (GRACE). Heart 2003,
89(9):1003-1008.
39. Fox KA, Dabbous OH, Goldberg RJ, Pieper KS, Eagle KA, Van de Werf F,
Avezum A, Goodman SG, Flather MD, Anderson FA Jr, et al: Prediction of
risk of death and myocardial infarction in the six months after
presentation with acute coronary syndrome: prospective multinational
observational study (GRACE). BMJ 2006, 333(7578):1091.
40. Szummer K, Lundman P, Jacobson SH, Schon S, Lindback J, Stenestrand U,
Wallentin L, Jernberg T: Relation between renal function, presentation,
use of therapies and in-hospital complications in acute coronary
syndrome: data from the SWEDEHEART register. J Intern Med
268(1):40-49.
41. Gibson CM, Pinto DS, Murphy SA, Morrow DA, Hobbach HP, Wiviott SD,
Giugliano RP, Cannon CP, Antman EM, Braunwald E: Association of
creatinine and creatinine clearance on presentation in acute myocardial
infarction with subsequent mortality. J Am Coll Cardiol 2003,
42(9):1535-1543.
42. Januzzi JL, Cannon CP, DiBattiste PM, Murphy S, Weintraub W, Braunwald E:
Effects of renal insufficiency on early invasive management in patients
with acute coronary syndromes (The TACTICS-TIMI 18 Trial). Am J Cardiol
2002, 90(11):1246-1249.
43. Wright RS, Reeder GS, Herzog CA, Albright RC, Williams BA, Dvorak DL,
Miller WL, Murphy JG, Kopecky SL, Jaffe AS: Acute myocardial infarction
and renal dysfunction: a high-risk combination. Ann Intern Med 2002,
137(7):563-570.
44. Freeman RV, Mehta RH, Al Badr W, Cooper JV, Kline-Rogers E, Eagle KA:
Influence of concurrent renal dysfunction on outcomes of patients with
acute coronary syndromes and implications of the use of glycoprotein
IIb/IIIa inhibitors. J Am Coll Cardiol 2003, 41(5):718-724.
45. Tokmakova MP, Skali H, Kenchaiah S, Braunwald E, Rouleau JL, Packer M,
Chertow GM, Moye LA, Pfeffer MA, Solomon SD: Chronic kidney disease,
cardiovascular risk, and response to angiotensin-converting enzyme
inhibition after myocardial infarction: the Survival And Ventricular
Enlargement (SAVE) study. Circulation 2004, 110(24):3667-3673.
46. Szummer K, Lundman P, Jacobson SH, Schon S, Lindback J, Stenestrand U,
Wallentin L, Jernberg T: Influence of renal function on the effects of early
revascularization in non-ST-elevation myocardial infarction: data from
the Swedish Web-System for Enhancement and Development of
Evidence-Based Care in Heart Disease Evaluated According to
Recommended Therapies (SWEDEHEART). Circulation 2009,
120(10):851-858.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2261/11/37/prepub
doi:10.1186/1471-2261-11-37
Cite this article as: Kümler et al.: Renal function at the time of a
myocardial infarction maintains prognostic value for more than 10
years. BMC Cardiovascular Disorders 2011 11:37.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Kümler et al. BMC Cardiovascular Disorders 2011, 11:37
http://www.biomedcentral.com/1471-2261/11/37
Page 10 of 10